Form 4: Artivion Director Receives Equity Grant

Director Thomas F. Ackerman was granted 7,576 shares of common stock in Artivion, Inc. as part of an equity incentive plan.

Summary

• Director Thomas F. Ackerman acquired 7,576 shares of Artivion, Inc. (AORT) common stock.
• The shares were granted at a price of $0, representing a restricted stock award (RSA).
• Following this transaction, the director's total beneficial ownership increased to 157,472 shares.
• The grant is subject to a vesting schedule set for May 18, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity compensation.
• Increase in total beneficial ownership by a member of the board.

Negatives

• None identified.

Risks

• Standard market risks associated with equity-based compensation and stock price volatility.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to align board incentives with long-term company performance in the medical device sector.

Comparison to Industry Standards

• The use of restricted stock awards (RSAs) for director compensation is consistent with standard practices for mid-cap medical technology companies.
• The vesting period of one year is typical for annual director equity grants.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation practices.

Next Steps

• Vesting of the 7,576 shares on May 18, 2027.

Key Dates

Keywords

Artivion, AORT, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation